What is WGSWW's health score?

GeneDx Holdings Corp. (WGSWW) has a TradeApes health score of 32 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is WGSWW's estimated fair value?

Based on our 5-year discounted cash flow model, GeneDx Holdings Corp.'s estimated fair value is $11.75 per share, representing a -81.5% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is WGSWW undervalued or overvalued?

Our model currently rates WGSWW as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

To Unlock Full Report

4 free score cards remaining

GeneDx Holdings Corp. (WGSWW)

Healthcare Overvalued low weak

Updated: 2026-07-18

TradeApes Score

Financial Strength

15 Stressed

Operating Trend

20 Stressed

Relative Value

40 Weak

Capital Allocation

40 Weak

Risk Management

70 Healthy

Est. Fair Value $11.75

DCF Upside -81.5%

Key Findings

+ Active debt paydown — total debt declining more than 10% year over year

Unlock Full Report →

− High leverage — net debt/EBITDA between 3× and 5×

Unlock Full Report →

Industry Related Stocks

Acadia Healthcare Company, Inc. (ACHC) agilon health, inc. (AGL) Airsculpt Technologies, Inc. (AIRS) Ardent Health, Inc. (ARDT) Agape ATP Corp (ATPC) AUNA S.A. (AUNA)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.